According to Belgian research, Moderna’s COVID-19 vaccine produces twice as many antibodies as Pfizer’s vaccine.
The research, which was originally posted in the Journal of the American Medical Association (JAMA), featured a direct comparison of specific immune reactions of nearly 2,500 medical professionals who had never before caught COVID-19.
As per the data, the immunoglobulin levels among receivers of the two-dose Moderna vaccination were 2,881 units/mL on average, compared to 1,108 units/mL among users of the two-dose Pfizer vaccine.
The study provided two explanations for the huge variation in the number of antibodies produced by the two mRNA-based COVID-19 immunizations.
First, Moderna’s vaccine includes more active components than Pfizer’s. The former has 100 micrograms of active chemicals, whilst the latter includes just 30 micrograms.
Second, Moderna’s vaccine has a greater gap between doses than Pfizer. The former’s two doses are given four weeks apart, whilst the latter’s two doses are given three weeks apart.
American research published earlier this month discovered that Moderna’s vaccine decreases the risk of SARS-COV-2 by twice as much as Pfizer’s vaccination.